Skip to main content
Fig. 5 | Clinical Epigenetics

Fig. 5

From: The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells

Fig. 5

MPT0G211 potentiates vincristine-induced apoptosis in MOLT-4 cells. a The combined effects of MPT0G211 with doxorubicin (DOXO), vincristine (VCR), or cyclophosphamide (CTX) at the indicated concentrations were evaluated after a 48-h treatment. b Cell cycle distribution was determined after cells were treated with a combination of MPT0G211 and VCR for 48 h. c The combined effects of MPT0G211 and VCR on the expression of caspases 3, 8, and 9 and poly-ADP ribose polymerase (PARP). d Flow cytometry was used to evaluate the proportions of cells in the sub-G1 phase of cell cycle after incubation with 3 μM MPT0G211 or tubastatin A (TBA) together with 1 nM VCR for 48 h. Data are shown as means ± standard errors of the means. *p < 0.05, **p < 0.01, and ***p < 0.001 versus the control group

Back to article page